Skip to main content
    T

    Traws Pharma Inc (TRAW)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.26
    +0.01 (+3.59%)

    Market Cap: $3.86M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Traws Pharma Inc (TRAW) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Traws Pharma (TRAW) is expected to report earnings on Apr 13, 2027. In the quarter ended Jun 30, 2026, Traws Pharma reported EPS of -$0.16, above the -$0.22 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(24/36)
    Avg Surprise
    +40.00%
    Streak
    2 Q

    Upcoming Estimates

    Reports Apr 13, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.24
    Range-$0.28 - -$0.20
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    TRAW has an expected report date of Apr 13, 2027.

    TRAW Earnings Call

    The latest TRAW earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, TRAW beat 25, missed 10 and matched 2. The widest gap in the table came in the quarter ended Mar 31, 2025, when EPS landed 888.68% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.16-$0.22N/A+27.27%BeatN/A11 up, 0 downAug 13, 2026N/A
    Mar 31, 2026-$0.52-$0.56-$0.56 - -$0.56+7.14%Beat-124.9%11 up, 0 downApr 15, 2026N/A
    Dec 31, 2025-$0.55-$0.54-$0.54 - -$0.54-2.67%Miss-102.1%10 up, 0 downDec 31, 2025$2.62M
    Sep 30, 2025-$0.34-$9.16N/A+96.29%BeatN/AN/AN/ANov 13, 2025N/A
    Jun 30, 2025-$0.16-$8.75N/A+98.17%BeatN/AN/AN/AAug 14, 2025$2.73M
    Mar 31, 2025$2.09-$0.27N/A+888.68%BeatN/AN/AN/AMay 15, 2025$57000
    Dec 31, 2024$26.60-$0.25N/AN/AN/AN/AN/A0 up, 0 downMar 31, 2025$57000
    Sep 30, 2024-$8.81-$6.25N/A-40.96%MissN/AN/AN/ANov 14, 2024$57000
    Jun 30, 2024-$121.75-$6.25N/AN/AN/AN/AN/A0 up, 0 downAug 15, 2024$57000
    Mar 31, 2024-$5.00-$6.33N/A+21.01%BeatN/AN/A0 up, 0 downApr 1, 2024$56000
    Dec 31, 2023-$0.19-$0.25N/A+24.00%BeatN/AN/AN/AMar 14, 2024$56000
    Sep 30, 2023-$5.75-$7.25N/A+20.69%BeatN/AN/AN/ANov 14, 2023$57000
    Jun 30, 2023-$5.00-$7.81N/A+35.98%BeatN/AN/AN/AAug 10, 2023$57000
    Mar 31, 2023-$7.00-$7.44N/A+5.91%BeatN/AN/AN/AMay 15, 2023$56000
    Dec 31, 2022-$0.26-$0.26N/A0.00%In lineN/AN/AN/AMar 16, 2023$56000
    Sep 30, 2022-$6.50-$5.31N/A-22.41%MissN/AN/AN/ANov 14, 2022$57000
    Jun 30, 2022-$4.75-$4.94N/A+3.85%BeatN/AN/AN/AAug 11, 2022$57000
    Mar 31, 2022-$5.00-$4.69N/A-6.61%MissN/AN/AN/AMay 11, 2022$56000
    Dec 31, 2021-$0.17-$0.17N/A0.00%In lineN/AN/AN/AMar 17, 2022$56000
    Sep 30, 2021-$5.50-$8.17N/A+32.68%BeatN/AN/AN/ANov 11, 2021$57000
    Jun 30, 2021-$6.75-$7.12N/A+5.20%BeatN/AN/AN/AAug 12, 2021$57000
    Mar 31, 2021-$0.30-$0.45N/A+33.33%BeatN/AN/AN/AMay 17, 2021$56000
    Dec 31, 2020-$11.25-$13.12N/A+14.25%Beat-1078.3%N/AN/AMar 11, 2021$57000
    Sep 30, 2020-$11.25-$12.50N/A+10.00%BeatN/AN/AN/ANov 12, 2020$66000
    Jun 30, 2020-$15.00-$11.25N/A-33.33%MissN/AN/AN/AAug 12, 2020$56000
    Mar 31, 2020-$11.25-$20.62N/A+45.44%BeatN/AN/AN/AMay 14, 2020$52000
    Dec 31, 2019$1.15-$0.07N/AN/AN/AN/AN/AN/AMar 24, 2020$30000
    Sep 30, 2019-$281.25-$255.00N/A-10.29%MissN/AN/AN/ANov 12, 2019$63000
    Jun 30, 2019-$225.00-$330.00N/A+31.82%BeatN/AN/AN/AAug 14, 2019$2.02M
    Mar 31, 2019-$483.75-$388.12N/A-24.64%MissN/AN/AN/AMay 14, 2019$68000
    Dec 31, 2018-$0.98-$0.97N/A-1.03%MissN/AN/AN/AMar 26, 2019$59000
    Sep 30, 2018-$352.50-$435.00N/A+18.97%BeatN/AN/AN/ANov 13, 2018$120000
    Jun 30, 2018-$393.75-$431.25N/A+8.70%BeatN/AN/AN/AAug 14, 2018$485000
    Mar 31, 2018-$5.10-$5.85N/A+12.78%BeatN/AN/AN/AMay 15, 2018$564000
    Dec 31, 2017-$3,318.75-$3,867.19N/A+14.18%BeatN/AN/AN/AMar 8, 2018$143000
    Sep 30, 2017-$3,993.75-$3,895.31N/A-2.53%MissN/AN/AN/ANov 9, 2017$110000
    Jun 30, 2017-$1,631.25-$4,068.75N/A+59.91%BeatN/AN/AN/AAug 14, 2017$324000
    Mar 31, 2017-$6,918.75-$5,400.00N/A-28.13%MissN/AN/AN/AMay 15, 2017$210000
    Dec 31, 2016-$0.54-$15.00N/A+96.40%Beat-400.0%N/AN/AMar 27, 2017$173000
    Sep 30, 2016-$4,443.75-$4,612.50N/A+3.66%BeatN/AN/AN/ANov 14, 2016$1.65M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.04, a profit after a loss of $108.96 per share the year before. It was -$30,975.74 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.04N/A
    Dec 31, 2024-$108.96N/A
    Dec 31, 2023-$17.94N/A
    Dec 31, 2022-$16.51N/A
    Dec 31, 2021-$12.72N/A
    Dec 31, 2020-$48.75N/A
    Dec 31, 2019-$988.85N/A
    Dec 31, 2018-$752.33N/A
    Dec 31, 2017-$15,862.50N/A
    Dec 31, 2016-$30,975.74N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 2,500 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20252,5025
    2025Q2Jun 30, 20252,6986

    2025Q4 Earnings Call

    Opening remarks

    John Fraunces Host / Moderator, LifeSci Advisors Thank you, operator, and welcome, everyone, to Traws Pharma's Full Year 2025 Financial Results and Business Update Conference Call. This afternoon, Traws issued a press release reporting its 2025 financial results and provided a business update. If you have not yet seen this press release, it is available in the Investor Relations section of the company's website. Following my introduction, we will hear from Traws's Chief Executive Officer, Dr. Iain Dukes; and Chief Financial Officer, Charles Parker. Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Traws disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in this morning's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Traws's CEO, Dr. Iain Dukes.

    Iain Dukes Chief Executive Officer (CEO) Thanks, John, and thanks to everyone for joining us today. Over the last year, Traws has made substantial progress towards our objective of bringing our differentiated next-generation antiviral candidate for influenza to patients. This morning, Traws announced a private financing of $60 million. The private financing was supported by new and existing health care-focused investors. The capital from this financing positions Traws to advance the flu program through a human challenge study this summer while providing access to additional capital as we achieve further key milestones. Influenza is estimated to be a multibillion-dollar opportunity spanning prophylactic and therapeutic applications, including strategic government stockpiling and pandemic preparedness incentives. The human challenge study trial focused on flu prevention is an important step towards establishing the potential for tivoxavir marboxil as a potential best-in-class prophylactic agent for flu prevention. We intend to initiate the study this summer once we have approval received from the Medicines and Healthcare products Regulatory Agency, or MHRA, in the U.K. During today's call, we will provide an overview of development of our lead candidate, tivoxavir marboxil or tivoxavir for short, for influenza. Tivoxavir marboxil is an exciting next-generation investigational influenza antiviral that targets the highly conserved cap-dependent endonuclease. We believe tivoxavir is well positioned to become a best-in-class once-monthly oral prophylactic agent with additional potential for pandemic flu, including H5N1 bird flu. We will prioritize development of tivoxavir as a once-monthly prophylactic agent for influenza prevention.

    Frequently Asked Questions About TRAW

    When is Traws Pharma's next earnings date?

    Traws Pharma's next earnings report is expected for Apr 13, 2027.

    Did TRAW beat earnings estimates last quarter?

    Yes. Traws Pharma reported EPS of -$0.16 for the quarter ended Jun 30, 2026, above the -$0.22 estimate, a 27.27% surprise.

    What EPS do analysts expect from TRAW next quarter?

    The consensus EPS estimate for Traws Pharma for the quarter ending Dec 31, 2026 is -$0.24 from 4 analysts, with estimates from -$0.28 to -$0.20.

    How often does TRAW beat earnings estimates?

    Traws Pharma beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +136.87%.